| Document |
Document Title |
|
WO/2024/086928A1 |
The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding...
|
|
WO/2024/088424A1 |
Provided in the present disclosure is an antibody specifically binding to cytotoxic T lymphocyte-associated antigen-4 (CTLA4), particularly a heavy-chain antibody, and more particularly a single-domain antibody. Also disclosed is the the...
|
|
WO/2024/088390A1 |
The present invention provides a preparation containing an anti-Nectin-4 antibody drug conjugate (ADC) and a use thereof. The preparation comprises an ADC, a buffering agent and an excipient. The anti-Nectin-4 ADC in the preparation exis...
|
|
WO/2024/088176A1 |
The present invention relates to the field of biomedicine, and mainly relates to a vaccine design method for enhancing an antigen-presenting effect, which is applied to structural sequence design and preparation of nucleic acids, protein...
|
|
WO/2023/240050A9 |
The disclosure relates to compounds and methods for repurposing antibodies.
|
|
WO/2024/091979A1 |
The invention relates generally to engineered anti-CD276 antibodies containing one or more unnatural amino acids (UAAs), their conjugation with a payload to generate an antibody-payload (e.g., drug) conjugate, drug substances containing ...
|
|
WO/2024/091907A1 |
Provided herein are compositions, systems, and methods comprising effector proteins for treating HPV infections. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods...
|
|
WO/2024/091578A2 |
Methods of nuclear targeted DNA delivery are provided. Aspects of the methods include contacting a cell with: (a) a nuclear targeted deoxyribonucleic acid (NTDNA) that includes a DNA nuclear targeting sequence (DTS) and a cargo nucleic a...
|
|
WO/2024/090893A1 |
The present invention relates to extracellular vesicles (EVs) overexpressing fibronectin fragment protein, and a use for drug delivery thereof. The present invention relates to a method for increasing EV delivery efficiency into cells by...
|
|
WO/2024/088401A1 |
Provided are gene editing systems and methods for reducing cell immunogenicity and reducing graft versus host (GvH) response, or to promote the persistence of therapeutic cells. Also provided are polynucleotides, vectors, cells, kits and...
|
|
WO/2024/089629A1 |
An engineered, non-naturally occurring Cas12 protein, CRISPR-Cas system and uses thereof are provided. The engineered, non-naturally occurring novel Cas12 proteins comprise an amino acid sequence selected from SEQ ID NOs: 1-36, a homolog...
|
|
WO/2024/091053A1 |
The present invention relates to a method for predicting the response to immunotherapeutic agents, comprising a step of measuring, in cancer cells or cancer tissue, the expression level of a dexamethasone-induced ras-related protein 1 (D...
|
|
WO/2024/091540A1 |
The present disclosure relates to compositions and methods for the suppression of silencing of a gene of interest in plants. Also disclosed are vectors, transgenic plants and plant parts comprising genetic constructs for suppressing endo...
|
|
WO/2024/092199A1 |
The present disclosure provides polypeptide molecules comprising one or more polypeptide chains and systems, compositions, and methods of use thereof, wherein the polypeptide molecule comprising one or more polypeptide chains (or enginee...
|
|
WO/2024/091694A1 |
A chimeric protein encoded by an expression plasmid is provided. The chimeric protein comprises an extracellular of a pathogen-binding receptor and an intracellular domain of an innate immune signaling protein, such as the TLR family of ...
|
|
WO/2024/089634A1 |
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA is formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide a...
|
|
WO/2024/088435A1 |
Provided is a Pseudomonas sp. having a mutant of PHA polymerase PhaC61-3. The Pseudomonas sp. is fermented to produce a novel viscous polyhydroxyalkanoate, providing a new material for the preparation of degradable products.
|
|
WO/2024/087515A1 |
Provided are an anti-CD16A antibody and an application thereof. The antibody comprises heavy chain variable region CDR1, CDR2 and CDR3 sequences as shown in SEQ ID NOs: 1, 2 and 3 respectively, or amino acid sequences at least 95% identi...
|
|
WO/2024/090383A1 |
Provided is a production method of cells into which exogenous mitochondria have been introduced, the production method comprising culturing recipient cells using cell culture equipment in which mitochondria isolated from donor cells are ...
|
|
WO/2024/092258A2 |
Disclosed herein are novel transcription factors for promoting reprogramming of, and/or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting...
|
|
WO/2024/090872A1 |
The present invention relates to a method and a kit for rapidly diagnosing tsutsugamushi on the basis of genetic scissors. More specifically, the present invention relates: to a molecular diagnosis method for rapidly detecting Orientia t...
|
|
WO/2024/088325A1 |
The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
|
|
WO/2023/056252A9 |
Multispecific binding proteins that bind NKG2D receptor, CD 16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for...
|
|
WO/2024/092217A1 |
The present disclosure provides systems and methods for high throughput genetic manipulation. Particularly, systems and methods are provided for scalable gene insertions in mammalian cells, the systems and methods comprise a donor nuclei...
|
|
WO/2024/088808A1 |
Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery, whereby, upon intranasal administration the MEVs traffic through specific routes following intranasal administration to spe...
|
|
WO/2024/086919A1 |
The present disclosure provides antibodies or antigen-binding fragments thereof that bind specifically to integrin α11 (ITGA11). This disclosure also provides methods for treating a disorder in a subject, such as a fibrotic disorder, an...
|
|
WO/2024/090884A1 |
The present invention relates to a novel phenylalanine:H+ symporter PheP variant and a method for producing L-aromatic amino acids using same, wherein the protein activity of the phenylalanine:H+ symporter PheP variant changes as at leas...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/091909A1 |
Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subj...
|
|
WO/2024/090415A1 |
The present invention addresses the problem of providing lactic acid bacteria having high ability to activate innate immunity. The present invention also addresses the problem of providing: an innate immunity activator containing, as an ...
|
|
WO/2024/088371A1 |
An isolated antigen-binding protein capable of targeting MSLN. The isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence represented by any ...
|
|
WO/2024/090563A1 |
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species a...
|
|
WO/2024/088412A1 |
Disclosed are a TLR7-IFN I signaling pathway activated mouse in-vivo cell, a humanized systemic lupus erythematosus mouse having the cell, a construction method for the mouse, and a use of the mouse in medical research. Specifically, a T...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/086899A1 |
The present disclosure relates to a method of separation of charged substances by electrophoresis by using an inorganic thread. It includes contacting an electrolyte with an outer surface of the inorganic thread to cause wetting the oute...
|
|
WO/2024/090441A1 |
The purpose of the present invention is to provide single-round infectious particles that are derived from a virus belonging to the orthocoronavirus subfamily and in which not only the spike (S) protein on the surface of the virus belong...
|
|
WO/2024/091874A1 |
Disclosed herein are compositions comprising a MTRES1 gene therapy. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a MTRES1 gene therapy.
|
|
WO/2024/091990A1 |
Described are methods of treating human papillomavirus (HPV) type 16- or HPV type 18-related High-grade Squamous Intraepithelial Lesion (HSIL) of the cervix. The described methods comprise evaluating one or more biological samples for th...
|
|
WO/2024/092186A2 |
Described genetically modified Fragaria plants having increased resistance to anthracnose fruit rot. Compositions for modifying Fragaria plants to increase resistance to anthracnose fruit rot and methods of using the compositions to modi...
|
|
WO/2024/088051A1 |
The present invention relates to the field of biotechnology, and provides a cell wall synthesis-related protein UGMA, a gene encoding same, and a use thereof. The use of the cell wall synthesis-related protein UGMA or the gene encoding t...
|
|
WO/2024/087784A1 |
The present invention belongs to the technical field of genetic engineering and synthetic biology. Provided are a recombinant type XVII humanized collagen expressed in yeast and a preparation method therefor, and particularly provided ar...
|
|
WO/2024/090815A1 |
The present invention relates to a technology for producing human papillomavirus virus-like particles from a plant and, more specifically, to a technology for effectively producing human papillomavirus virus-like particles in a plant chl...
|
|
WO/2024/088396A1 |
Provided are an FNR mutant and the use thereof in gene expression regulation. The mutant has an R169G and/or a G216D mutation on the amino acid sequence of the FNR, and the amino acid sequence of the FNR is as shown in SEQ ID NO: 1, or h...
|
|
WO/2024/089663A1 |
The present disclosure relates to a method and a composition for the treatment/prevention of neurodegenerative diseases, in particular Machado-Joseph disease (MJD)/ Spinocerebellar Ataxia type-3 (SCA3) by utilizing extracellular vesicles...
|
|
WO/2024/088404A1 |
This disclosure provides engineered 4-1BBL variants, and methods of use thereof.
|
|
WO/2024/087405A1 |
A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.
|
|
WO/2024/090413A1 |
The present invention addresses the problem of providing a lactic acid bacterium having high natural immunoactivating capability. The present invention also addresses the problem of providing: a natural immunoactivator which contains, as...
|
|
WO/2024/088372A1 |
A method for efficiently and rapidly obtaining stable apple transgenic plants by using Agrobacterium rhizogenes. In the method, apple leaves are used as receptors to obtain adventitious buds instead of hairy roots through the mediation o...
|
|
WO/2024/090440A1 |
It was discovered that, by using (a) FDC in which position 397 is tryptophan, position 398 is methionine, position 440 is tyrosine, and position 189 is methionine and/or (b) FDC in which position 397 is tryptophan, position 398 is methio...
|
